CV and Bibliography

Yukio Kato, Ph.D.


Associate Professor
Division of Pharmaceutical Sciences
Graduate School of Natural Science and Technology
Kanazawa University
Kakuma-machi, Kanazawa 920-1192, JAPAN

Present Business Address:

Division of Pharmaceutical Sciences,
Graduate School of Natural Science and Technology, Kanazawa University
Kakuma-machi, Kanazawa 920-0934, Japan
[TEL] +81-76-234-4478 [FAX] +81-76-264-6284
[E-mail] ykato@p.kanazawa-u.ac.jp

Research and/or Professional Experiences:

1993 Fellowship of the Japan Society for the Promotion of Science for Japanese Junior Scientists
1993-1997 Research Associate
Faculty of Pharm. Sci., Univ. of Tokyo
1997-2001 Research Associate
Graduate School of Pharm. Sci., Univ. of Tokyo
2001-2002 Visiting Fellow
Cell Biology and Metabolism Branch, National Institute of Child Health, National Institutes of Health, USA
2002-present Associate Professor
Faculty of Pharm. Sci., Kanazawa Univ

Publication:

(1) 94 original articles (written in English)

(2) 7 review articles and/or book chapters (written in English)

(3) 16 review articles and/or book chapters (written in Japanese)

Awards:

1) Banyu Young Scientist Award for Pharmaceutics (Sep 22, 2000)

2) ISSX New Investigator Award in Asia-Pacific region (May 26, 2006)

3) JSSX New Investigator Award (Nov 29, 2006)

Invited Lectures (International):

  1. Yuichi Sugiyama and Yukio Kato. Kinetic analysis of receptor-mediated clearance of cytokines.  The advances in pharmaceutical sciences: National University of Singapore (NUS) - Japan Society for the Promotion of Science (JSPS) Seminar, December 8-10, 1994, University of Singapore, Singapore.

  2. Yukio Kato and Yuichi Sugiyama. Targeting Delivery of Cytokines by Use of Receptor-Mediated Endocytosis. 8th Japanese-American Conference on Pharmacokinetics and Biopharmaceutics, July 29-30, 1996, Kane Hall, University of Washington, Seattle.

  3. Yuichi Sugiyama and Yukio Kato. First Symposium on Advances in Technology and Business Potential of New Drug Delivery Systems, February 27-28, 1998, Centaur Hotel, Mumbai, India.

  4. Yukio Kato. Kinetic and biochemical analysis of receptor-mediated endocytosis : Influence of receptor up- and down-regulation on the clearance and the pharmacological effects of cytokines. The 3rd International Symposium on Measurement and Kinetics of In vivo Drug Effects, May 27-30, 1998, Leeuwenhorst Congress Centre, Noordwijkerhout, The Netherlands.

  5. Yukio Kato and Yuichi Sugiyama. Prediction of Transporter-Mediated Drug-Drug Interactions Based on In-Vitro Data Obtained using Isolated Cells and Membrane Vesicles. AAPS Workshop on Drug-Drug and Drug-Food Interactions: Mechanisms, Predictions & Regulatory Implications, December 8-10, 1999, Crystal Gateway Marriott, Arlington, Virginia.

  6. Yukio Kato, Hiroshi Suzuki and Yuichi Sugiyama. Toxicological implications of hepatobiliary transporters. The 9th international congress of toxicology, July 8-12, 2001, Brisbane Convention Centre, Brisbane, Australia.

  7. Yukio Kato, Yoshiyuki Kubo and Akira Tsuji. Regulation of xenobiotic transporters by interaction with PDZ adaptor proteins: Its implications in drug disposition. 5th Retrometabolism Based Drug Design and Targeting Conference, May 8-11, 2005, Hakone Hotel Kowaki-en, Hakone, JAPAN.

  8. Yukio Kato, Yoshiyuki Kubo and Akira Tsuji. Protein-protein interaction involved in regulation of function and expression of organic cation/carnitine transporter OCT/OCTN family. 4th International Research Conference: Biomedical Transporters 2005 gMembrane transporters: Bridging basic and applied sciences, h August 14-18, 2005, OLMA Congress Center, St. Gallen, Switzerland.

  9. Yukio Kato. Interactions of SLC Xenobiotic Transporters with PDZ-Domain Containing Proteins and their Implications in Drug Disposition 13th North American ISSX/20th JSSX Meeting, The Outrigger Hotel, October 23-27, 2005, Maui, Hawaii.

  10. Yukio Kato, Yoshiyuki Kubo and Akira Tsuji. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. 9th European Symposium on Controlled Drug Delivery, April 5-7, 2006, Noordwijk aan Zee, Netherlands.

  11. Yukio Kato, Yoshiyuki Kubo and Akira Tsuji. PDZ adaptor proteins as regulatory mechanisms for organic cation/carnitine transporter OCT/OCTN family. The 3rd Korea-Japan Joint Symposium on Drug Delivery and Therapy, April 20-21, 2006, Hoam Faculty Center of Seoul National University, Korea.


Major Research Interests:

(1) Protein interaction and functional regulation of xenobiotic transporters

(2) Transporter-mediated drug absorption, distribution and disposition

Membership:

(1) International Society for the Study of Xenobiotics (ISSX)

(2) American Society for Cell Biology (ASCB)

(3) The Japanese Society for the Study of Xenobiotics (JSSX)

(4) The Pharmaceutical Society of Japan (PSJ)

(5) The Academy of Pharmaceutical Science and Technology, Japan (APSTJ)

Original Articles in Refereed Journals:

  1. Protein interaction relevant to functional regulation/coupling of receptors and transporters

    1) Misra S, Puertollano R, Kato Y, Bonifacino JS, Hurley JH. Structural basis for acidic-cluster-dileucine sorting-signal recognition by VHS domains. Nature. 415(6874): 933-937, 2002.

    2) Kato Y, Misra S, Puertollano R, Hurley JH, Bonifacino JS. Phosphoregulation of sorting signal-VHS domain interactions by a direct electrostatic mechanism. Nat Struct Biol. 9(7): 532-536, 2002.

    3) Janvier K, Kato Y, Boehm M, Rose JR, Martina JA, Kim BY, Venkatesan S, Bonifacino JS. Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 delta-sigma3 hemicomplexes. J Cell Biol. 163(6): 1281-1290, 2003.

    4) Kato Y, Yoshida K, Watanabe C, Sai Y, Tsuji A. Screening of the interaction between xenobiotic transporters and PDZ proteins. Pharm Res. 21(10): 1886-1894, 2004.

    5) Kato Y, Sai Y, Yoshida K, Watanabe C, Hirata T, Tsuji A. PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. Mol Pharmacol. 67(3): 734-743, 2005.

    6) Watanabe C, Kato Y, Ito S, Kubo Y, Sai Y and Akira Tsuji. Na+/ H+ exchanger 3 affects transport property of H+/oligopeptide transporter 1. Drug Metab Pharmacokinet. 20(6): 443-451, 2005.

    7) Sugiura T, Kato Y, Kubo Y and Tsuji A. Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2. Drug Metab Pharmacokin. 21(5): 375-383, 2006.

    8) Kato Y, Sugiura M, Sugiura T, Wakayama T, Kubo Y, Kobayashi D, Sai Y, Tamai I, Iseki S, Tsuji A. Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. Mol Pharmacol. 70(3): 829-837, 2006.

    9) Watanabe C, Kato Y, Sugiura T, Kubo Y, Wakayama T, Iseki S and Tsuji A. PDZ adaptor protein PDZK2 stimulates transport activity of organic cation/carnitine transporter OCTN2 by modulating cell-surface expression. Drug Metab Dispos. 34(11): 1927-1934, 2006 and Cover Caption of Vol. 34(11).

    10) Sato T, Mushiake S, Kato Y, Sato K, Sato M, Takeda N, Ozono K, Miki K, Kubo Y, Tsuji A, Harada R, Harada A. The Rab8 GTPase regulates apical protein localisation in intestinal cells. Nature, in press.


  2. Transporter-mediated drug absorption, distribution and disposition

    1) Shin HC, Kato Y, Shitara Y, Yamada T, Nakamura T, Hisaka A, Sugiyama Y. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123. J Pharmacol Exp Ther. 278(2): 607-613, 1996.

    2) Shin HC, Kato Y, Yamada T, Niinuma K, Hisaka A, Sugiyama Y. Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. Am J Physiol. 272(5 Pt 1): G979-G986, 1997.

    3) Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther. 281(1): 304-314, 1997.
    4) Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 57(10): 1934-1938, 1997.

    5) Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, Sugiyama Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 57(16): 3506-3510, 1997.

    6) Sasabe H, Kato Y, Tsuji A, Sugiyama Y. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. J Pharmacol Exp Ther. 284(2): 661-668, 1998.

    7) Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 58(22): 5137-5143, 1998.

    8) Kato Y, Akhteruzzaman S, Hisaka A, Sugiyama Y. Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. J Pharmacol Exp Ther. 288(2): 568-574, 1999.

    9) Akhteruzzaman S, Kato Y, Hisaka A, Sugiyama Y. Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane. J Pharmacol Exp Ther. 288(2): 575-581, 1999.

    10) Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther. 288(2): 735-741, 1999.

    11) Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. Primary active transport of organic anions on bile canalicular membrane in humans. Am J Physiol. 276(5 Pt 1): G1153-G1164, 1999.

    12) Sasabe H, Kato Y, Terasaki T, Tsuji A, Sugiyama Y. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. Biopharm Drug Dispos. 20(3): 151-158, 1999.

    13) Chu XY, Kato Y, Sugiyama Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab Dispos. 27(4): 440-441, 1999.

    14) Han YH, Kato Y, Kusuhara H, Suzuki H, Shimoda M, Kokue E, Sugiyama Y. Kinetic profile of overall elimination of 5-methyltetrahydropteroylglutamate in rats. Am J Physiol. 276(3 Pt 1): E580-E587, 1999.

    15) Kino I, Kato Y, Lin JH, Sugiyama Y. Renal handling of biphosphonate alendronate in rats. Biopharm Drug Dispos. 20(4): 193-198, 1999.

    16) Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, Stieger B, Meier PJ, Sugiyama Y. Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. J Pharmacol Exp Ther. 290(3): 1107-1115, 1999.

    17) Han YH, Kato Y, Sugiyama Y. Nonlinear disposition kinetics of a novel antifolate, MX-68, in rats. J Pharmacol Exp Ther. 291(1): 204-212, 1999.

    18) Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, Sugiyama Y. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther. 292(1): 433-439, 2000.

    19) Han YH, Kato Y, Sugiyama Y. Binding and transport of methotrexate and its derivative, MX-68, across the brush-border membrane in rat kidney. Biopharm Drug Dispos. 20(8): 361-367, 1999.

    20) Liu KX, Kato Y, Kaku TI, Santa T, Imai K, Yagi A, Ishizu T, Sugiyama Y. Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. J Pharmacol Exp Ther. 294(2): 510-515, 2000.

    21) Nishino A, Kato Y, Igarashi T, Sugiyama Y. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan. Drug Metab Dispos. 28(10): 1146-1148, 2000.

    22) Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y. Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). Pharm Res. 18(5): 579-586, 2001.

    23) Han YH, Kato Y, Watanabe Y, Terao K, Asoh Y, Sugiyama Y. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats. Drug Metab Dispos. 29(4 Pt 1): 394-400, 2001.

    24) Ueda K, Kato Y, Komatsu K, Sugiyama Y. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J Pharmacol Exp Ther. 297(3): 1036-1043, 2001.

    25) Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res.19(2): 147-153, 2002.

    26) Gotoh Y, Kato Y, Stieger B, Meier PJ, Sugiyama Y. Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats. Am J Physiol Endocrinol Metab. 282(6): E1245-E1254, 2002.

    27) Kato Y, Kuge K, Kusuhara H, Meier PJ, Sugiyama Y. Gender difference in the urinary excretion of organic anions in rats. J Pharmacol Exp Ther. 302(2): 483-489, 2002.

    28) Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 302(2): 510-515, 2002.

    29) Horikawa M, Kato Y, Sugiyama Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res. 19(9): 1345-1353, 2002.

    30) Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, Sugiyama Y. Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. Drug Metab Dispos. 30(12): 1393-1399, 2002.

    31) Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The Potential for an Interaction between MRP2 (ABCC2) and Various Therapeutic Agents: Probenecid as a Candidate Inhibitor of the Biliary Excretion of Irinotecan Metabolites. Drug Metab Pharmacokinet. 17(1): 23-33, 2002.

    32) Horikawa M, Kato Y, Tyson CA, Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet. 18(1): 16-22, 2003.

    33) Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y. Function of uptake transporters for taurocholate and estradiol 17beta-d-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet. 18(1): 33-41, 2003.  

    34) Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol. 63(4): 844-848, 2003.

    35) Li Q, Sai Y, Kato Y, Tamai I, Tsuji A. Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm Res. 20(8): 1119-1124, 2003.

    36) Yagi Y, Shibutani S, Hodoshima N, Ishiwata K, Okudaira N, Li Q, Sai Y, Kato Y, Tsuji A. Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. Drug Metab Pharmacokinet. 18(6): 381-389, 2003.

    37) Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A. Transporter-mediated renal handling of nafamostat mesilate. J Pharm Sci. 93(2): 262-272, 2004.

    38) Inano A, Sai Y, Kato Y, Tamai I, Ishiguro M, Tsuji A. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition. Drug Metab Pharmacokinet. 19(3): 180-189, 2004.

    39) Nishimura T, Kato Y, Sai Y, Ogihara T, Tsuji A. Characterization of renal excretion mechanism for a novel diuretic, M17055, in rats. J Pharm Sci. 93(10): 2558-2566, 2004.

    40) Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. Differential involvement of multidrug resistance-associated protein 1 and p-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J Pharmacol Exp Ther. 310(2): 648-655, 2004.

    41) Kawasaki Y, Kato Y, Sai Y, Tsuji A. Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population. J Pharm Sci. 93(12): 2920-2926, 2004.

    42) Li Q, Kato Y, Sai Y, Imai T, Tsuji A. Multidrug resistance?associated protein 1 functions as an efflux pump of xenobiotics in the skin. Pharm. Res. 22(6):842-846, 2005.

    43) Sai Y, Kato Y, Nakamura K, Kato S, Nishimura T, Kubo Y, Tamai I, Yang S, Hu Z, Yamada I and Tsuji A. Carrier-mediated hepatic uptake of a novel non-renal excretion type uric acid generation inhibitor, Y-700. J Pharm Sci. 95(2): 336-347, 2006.

    44) Li Q, Tsuji H, Kato Y, Sai Y, Kubo Y, Tsuji A. Characterization of the Transdermal Transport of Flurbiprofen and Indomethacin. J Control Rel. 110(3): 542-556, 2006.

    45) Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos. 34(8): 1423-1431, 2006.

    46) Nishimura T, Kubo Y, Kato Y, Sai Y, Ogihara T and Tsuji A. Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: Involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res. 24(1): 90-98, 2007.

    47) Mitsuoka K, Kato Y, Kubo Y, Tsuji A. Functional expression of stereoselective metabolism of cephalexin by exogenous transfection of oligopeptide transporter PEPT1. Drug Metab Dispos. 35(3): 356-362, 2006.


  3. Receptor-mediated endocytosis relevant to tissue-specific targeting and disposition of biologically active proteins

    1) Kato Y, Sato H, Ichikawa M, Suzuki H, Sawada Y, Hanano M, Fuwa T, Sugiyama Y. Existence of two pathways for the endocytosis of epidermal growth factor by rat liver: phenylarsine oxide-sensitive and -insensitive pathways. Proc Natl Acad Sci USA. 89(18): 8507-8511, 1992.

    2) Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, Nakamura T, Sugiyama Y. Importance of the liver in plasma clearance of hepatocyte growth factors in rats. Am J Physiol. 263(5 Pt 1):G642-G649, 1992.

    3) Kato Y, Sugiyama Y. Binding, internalization, degradation, and mitogenic effect of epidermal growth factor in cultured rat hepatocytes. STP Pharm Sciences 3(1): 75-82, 1993.

    4) Liu KX, Kato Y, Yamazaki M, Higuchi O, Nakamura T, Sugiyama Y. Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride-intoxicated rats. Hepatology. 17(4): 651-660, 1993.

    5) Ichikawa M, Kato Y, Miyauchi S, Sawada Y, Iga T, Fuwa T, Hanano M, Sugiyama Y. Effect of perfusate pH on the influx of 5-5'-dimethyl-oxazolidine-2,4-dione and dissociation of epidermal growth factor from the cell-surface receptor: the existence of the proton diffusion barrier in the Disse space. J Hepatol. 20(2): 190-200, 1994.

    6) Kato Y, Liu KX, Nakamura T, Sugiyama Y. Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity. Hepatology. 20(2): 417-424, 1994.

    7) Liu KX, Kato Y, Terasaki T, Nakamura T, Sugiyama Y. Change in hepatic handling of hepatocyte growth factor during liver regeneration in rats. Am J Physiol. 269(5 Pt 1): G745-G753, 1995.

    8) Liu KX, Kato Y, Terasaki T, Aoki S, Okumura K, Nakamura T, Sugiyama Y. Contribution of parenchymal and non-parenchymal liver cells to the clearance of hepatocyte growth factor from the circulation in rats. Pharm Res. 12(11): 1737-1740, 1995.

    9) Hamada T, Kato Y, Terasaki T, Sugiyama Y. Cell density-dependent mitogenic effect and -independent cellular handling of epidermal growth factor in primary cultured rat hepatocytes. J Hepatol. 26(2): 353-360, 1997.

    10) Kozu A, Kato Y, Shitara Y, Hanano M, Sugiyama Y. Kinetic analysis of transcytosis of epidermal growth factor in Madin-Darby canine kidney epithelial cells. Pharm Res. 14(9): 1228-1235, 1997.

    11) Liu KX, Kato Y, Kato M, Kaku TI, Nakamura T, Sugiyama Y. Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. Am J Physiol. 273(5 Pt 1): E891-E897, 1997.

    12) Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics. Drug Metab Dispos. 25(9): 1039-1044, 1997.

    13) Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther. 283(2): 520-527, 1997.

    14) Liu KX, Kato Y, Kaku TI, Matsumoto K, Nakamura T, Sugiyama Y. Protamine enhances the proliferative activity of hepatocyte growth factor in rats. Am J Physiol. 274(1 Pt 1): G21-G28, 1998.

    15) Shitara Y, Kato Y, Sugiyama Y. Effect of brefeldin A and lysosomotropic reagents on intracellular trafficking of epidermal growth factor and transferrin in Madin-Darby canine kidney epithelial cells. J Control Release. 55(1): 35-43, 1998.

    16) Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Pharmacokinetics of erythropoietin in genetically anemic mice. Drug Metab Dispos. 26(2): 126-131, 1998.

    17) Liu KX, Kato Y, Kino I, Nakamura T, Sugiyama Y. Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. Am J Physiol. 275(5 Pt 1): E835-E842, 1998.

    18) Kato M, Kato Y, Nakamura T, Sugiyama Y. Efficient extraction by the liver governs overall elimination of hepatocyte growth factor in rats. J Pharmacol Exp Ther. 290(1): 373-379, 1999.

    19) Kato M, Kato Y, Sugiyama Y. Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. Am J Physiol. 276(5 Pt 1):E887-E895, 1999.

    20) Nishiyama N, Kato Y, Sugiyama Y, Kataoka K. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm Res. 18(7): 1035-1041, 2001.

    21) Mizuno N, Kato Y, Iwamoto M, Urae A, Amamoto T, Niwa T, Sugiyama Y. Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. Pharm Res. 18(8): 1203-1209, 2001.

    22) Shirota K, Kato Y, Suzuki K, Sugiyama Y. Characterization of novel kidney-specific delivery system using an alkylglucoside vector. J Pharmacol Exp Ther. 299(2): 459-467, 2001.

    23) Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J Control Release. 77(1-2): 27-38, 2001.

    24) Sato H, Kato Y, Hayasi E, Tabata T, Suzuki M, Takahara Y, Sugiyama Y. A novel hepatic-targeting system for therapeutic cytokines that delivers to the hepatic asialoglycoprotein receptor, but avoids receptor-mediated endocytosis. Pharm Res. 19(11): 1736-1744, 2002.

    25) Maeda K, Kato Y, Sugiyama Y. pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. J Control Release. 82(1): 71-82, 2002.

    26) Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 63(24): 8977-8983, 2003.

    27) Komoriya K, Kato Y, Hayashi Y, Ohsuye K, Nishigaki R, Sugiyama Y. Characterization of the hepatic disposition of lanoteplase, a rationally designed variant of tissue plasminogen activator in rodents. Drug Metab Dispos. 35(3):469-475, 2006.


  4. Other papers related to drug metabolism and disposition

    1) Mizuno N, Kato Y, Izumi Y, Irimura T, Sugiyama Y. Importance of hepatic first-pass removal in metastasis of colon carcinoma cells. J Hepatol. 28(5): 865-877, 1998.

    2) Mizuno N, Kato Y, Shirota K, Izumi Y, Irimura T, Harashima H, Kiwada H, Motoji N, Shigematsu A, Sugiyama Y. Mechanism of initial distribution of blood-borne colon carcinoma cells in the liver. J Hepatol. 28(5): 878-885, 1998.

    3) Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 28(10): 1238-1243, 2000.

    4) Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 18(8): 1190-1202, 2001.

    5) Tsukamoto Y, Kato Y, Ura M, Horii I, Ishikawa T, Ishitsuka H, Sugiyama Y. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model. Biopharm Drug Dispos. 22(1): 1-14, 2001.

    6) Nishimura T, Amano N, Kubo Y, Ono M, Kato Y, Fujita H, Kimura Y, Tsuji A. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab Dispos., in press.


  5. Other collaboration studies

    1) Liu KX, Kato Y, Kaku T, Sugiyama Y. Human placental extract stimulates liver regeneration in rats. Biol Pharm Bull. 21(1): 44-49, 1998.

    2) Shirota K, Kato Y, Irimura T, Kondo H, Sugiyama Y. Anti-metastatic effect of the sialyl Lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse. Biol Pharm Bull. 24(3): 316-319, 2001.

    3) Wakayama T, Kato Y, Utsumi R, Tsuji A, Iseki S. A time- and cost-saving method of producing rat polyclonal antibodies. Acta Histochem Cytochem 39(3): 79-87, 2006

    4) Wakayama T, Sai Y, Ito A, Kato Y, Kurobo M, Murakami Y, Nakashima E, Tsuji A, Kitamura Y, Iseki S. Heterophilic Binding of the Adhesion Molecules Poliovirus Receptor and Immunoglobulin Superfamily 4A in the Interaction Between Mouse Spermatogenic and Sertoli Cells. Biol Reprod 76(6): 1081-1090, 2007.


Review papers and book chapters (only in English)

1) Sugiyama Y and Kato Y: In vitro models of hepatic uptake: Methods to determine kinetic parameters for receptor-mediated hepatic uptake. In: "Peptide-Based Drug Design: Controlling Transport and Metabolism," edited by M. D. Taylor and G. L. Amidon, American Chemical Society Books Department, Washington, DC, USA, pp525-551, 1995.

2) Kato Y and Sugiyama Y. Peptide and protein delivery targeted to receptor-mediated endocytosis. Crit Rev Ther Drug Carrier Systems. 14(3): 173-219, 1997.

3) Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol. 42 Suppl: S44-S49, 1998.

4) Haas M, Kato Y, Haverdings RFG, Moolenaar F, Suzuki K, de Zeeuw D, Sugiyama Y and Meijer DKF. Delivery of drugs and antisense oligonucleotides to the proximal tubular cell of the kidney using macromolecular and pro°drug approaches. In: "Drug Targeting: Organ°specific strategies," edited by G. Molema and D.K.F. Meijer, Wiley°VCH, pp121-155, 2001.

5) Kato Y, Suzuki H, Sugiyama Y. Toxicological implications of hepatobiliary transporters. Toxicology. 181-182: 287-290, 2002.

6) Kato Y, Watanabe C, Tsuji A. Regulation of drug transporters by PDZ adaptor proteins and nuclear receptors. Eur J Pharm Sci, (review) 27(5): 487-500, 2006.

7) Sugiura T, Kato Y, Tsuji A. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. J Controlled Rel. (review) 116(2): 238-246, 2006.